View Financial HealthStarsource Multitrade 배당 및 자사주 매입배당 기준 점검 0/6Starsource Multitrade 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updatesReported Earnings • Aug 16First quarter 2027 earnings released: EPS: ₹0.14 (vs ₹78.70 loss in 1Q 2026)First quarter 2027 results: EPS: ₹0.14 (up from ₹78.70 loss in 1Q 2026). Revenue: ₹745.9k (up 260% from 1Q 2026). Net income: ₹209.8k (up ₹118.3m from 1Q 2026). Profit margin: 28% (up from net loss in 1Q 2026). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 133 percentage points per year, which is a significant difference in performance.공고 • Aug 11Starsource Multitrade Limited to Report Q1, 2027 Results on Aug 14, 2026Starsource Multitrade Limited announced that they will report Q1, 2027 results on Aug 14, 2026New Risk • Jul 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 77% per year over the past 5 years. Revenue is less than US$1m (₹5.5m revenue, or US$58k). Market cap is less than US$10m (₹139.0m market cap, or US$1.46m). Minor Risk Share price has been volatile over the past 3 months (7.7% average weekly change).Reported Earnings • May 31Full year 2026 earnings released: ₹79.03 loss per share (vs ₹2.28 profit in FY 2025)Full year 2026 results: ₹79.03 loss per share (down from ₹2.28 profit in FY 2025). Revenue: ₹5.50m (down 11% from FY 2025). Net loss: ₹118.5m (down ₹122.0m from profit in FY 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 171 percentage points per year, which is a significant difference in performance.공고 • May 25Starsource Multitrade Limited to Report Q4, 2026 Results on May 29, 2026Starsource Multitrade Limited announced that they will report Q4, 2026 results on May 29, 2026Reported Earnings • Feb 14Third quarter 2026 earnings released: ₹0.58 loss per share (vs ₹1.17 loss in 3Q 2025)Third quarter 2026 results: ₹0.58 loss per share (improved from ₹1.17 loss in 3Q 2025). Net loss: ₹865.1k (loss narrowed 51% from 3Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 165 percentage points per year, which is a significant difference in performance.공고 • Feb 09Starsource Multitrade Limited to Report Q3, 2026 Results on Feb 12, 2026Starsource Multitrade Limited announced that they will report Q3, 2026 results on Feb 12, 2026공고 • Nov 10Starsource Multitrade Limited to Report Q2, 2026 Results on Nov 13, 2025Starsource Multitrade Limited announced that they will report Q2, 2026 results on Nov 13, 2025New Risk • Oct 03New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 8.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.3% average weekly change). Earnings have declined by 47% per year over the past 5 years. Revenue is less than US$1m (₹3.4m revenue, or US$38k). Market cap is less than US$10m (₹198.0m market cap, or US$2.23m).공고 • Sep 26+ 2 more updatesChemo Pharma Laboratories Limited Announces Changes to Its BoardChemo Pharma Laboratories Limited Limited announced in the 83rd annual general meeting held on September 24, 2025, the company approved the appointment and regularization of Ms. Sarvagya Goel as independent director of the company, appointment and regularization of Ms. Shiply Chopra as Independent Director of the company, appointment and regularization of Ms. Simran Utsav Trivedi as independent director of the company and appointment and regularization of Mr. Utsav trivedi as Executive director. Appointment and regularization of ruchit Mehta as Managing director.New Risk • Sep 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 47% per year over the past 5 years. Revenue is less than US$1m (₹3.4m revenue, or US$38k). Market cap is less than US$10m (₹187.0m market cap, or US$2.12m). Minor Risk Share price has been volatile over the past 3 months (6.6% average weekly change).New Risk • Aug 14New major risk - Revenue and earnings growthEarnings have declined by 47% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 47% per year over the past 5 years. Revenue is less than US$1m (₹3.4m revenue, or US$39k). Market cap is less than US$10m (₹202.4m market cap, or US$2.31m).공고 • Aug 13Chemo Pharma Laboratories Limited, Annual General Meeting, Sep 24, 2025Chemo Pharma Laboratories Limited, Annual General Meeting, Sep 24, 2025, at 16:00 Indian Standard Time.공고 • Aug 05Chemo Pharma Laboratories Limited to Report Q1, 2026 Results on Aug 12, 2025Chemo Pharma Laboratories Limited announced that they will report Q1, 2026 results on Aug 12, 2025Valuation Update With 7 Day Price Move • May 26Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹146, the stock trades at a trailing P/E ratio of 56.1x. Average trailing P/E is 26x in the Diversified Financial industry in India. Total returns to shareholders of 306% over the past three years.공고 • May 14Chemo Pharma Laboratories Limited to Report Q4, 2025 Results on May 29, 2025Chemo Pharma Laboratories Limited announced that they will report Q4, 2025 results on May 29, 2025공고 • Apr 23Chemo Pharma Laboratories Limited Approves the Appointment of Bhawna Rajput as Company Secretary and Compliance Officer, Effective 16 April, 2025Chemo Pharma Laboratories Limited announced that at the board meeting held on April 16, 2025, approved the appointment of CS Bhawna Rajput as Company Secretary and Compliance Officer of the Company with effect from 16 April, 2025.공고 • Apr 08+ 2 more updatesChemo Pharma Laboratories Limited Announces Board and Executive ResignationsChemo Pharma Laboratories Limited announced the resignation of Mr. Bhavin Sheth from the position of Executive Director of the Company; resignation of Shri. Ashok Somani from the position of Executive Director of the Company; resignation of Mrs. Shanta Somani from the position of Non-Executive Director of the Company; resignation of Shri. Mathura Prasad Sharma, from the position of Directorship of the Company in the category of Non-Executive Independent Director; resignation of Shri Toby Antony from the position of Directorship of the Company in the category of Non- Executive Independent Director; resignation of Shri Nandkumar Pareek from the position of Directorship of the Company in the category of Non-Executive Independent Director; resignation of Mrs. Unnatti Jain, from the position of Company Secretary and Compliance Officer of the Company.Valuation Update With 7 Day Price Move • Feb 12Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹63.05, the stock trades at a trailing P/E ratio of 24.2x. Average trailing P/E is 25x in the Diversified Financial industry in India. Total returns to shareholders of 45% over the past three years.New Risk • Jan 28New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 38% Last year net profit margin: 90% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Revenue is less than US$1m (₹10m revenue, or US$119k). Market cap is less than US$10m (₹127.7m market cap, or US$1.48m). Minor Risk Profit margins are more than 30% lower than last year (38% net profit margin).공고 • Jan 13Chemo Pharma Laboratories Limited to Report Q3, 2025 Results on Jan 27, 2025Chemo Pharma Laboratories Limited announced that they will report Q3, 2025 results on Jan 27, 2025Valuation Update With 7 Day Price Move • Dec 19Investor sentiment deteriorates as stock falls 22%After last week's 22% share price decline to ₹98.45, the stock trades at a trailing P/E ratio of 11.9x. Average trailing P/E is 29x in the Diversified Financial industry in India. Total returns to shareholders of 234% over the past three years.Valuation Update With 7 Day Price Move • Dec 04Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹93.82, the stock trades at a trailing P/E ratio of 11.3x. Average trailing P/E is 27x in the Diversified Financial industry in India. Total returns to shareholders of 206% over the past three years.Valuation Update With 7 Day Price Move • Nov 04Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹82.72, the stock trades at a trailing P/E ratio of 10x. Average trailing P/E is 29x in the Diversified Financial industry in India. Total returns to shareholders of 172% over the past three years.공고 • Oct 15Chemo Pharma Laboratories Limited to Report Q2, 2025 Results on Oct 28, 2024Chemo Pharma Laboratories Limited announced that they will report Q2, 2025 results on Oct 28, 2024Valuation Update With 7 Day Price Move • Oct 10Investor sentiment improves as stock rises 31%After last week's 31% share price gain to ₹86.07, the stock trades at a trailing P/E ratio of 12.1x. Average trailing P/E is 28x in the Diversified Financial industry in India. Total returns to shareholders of 246% over the past three years.New Risk • Aug 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m (₹17m revenue, or US$204k). Market cap is less than US$10m (₹107.8m market cap, or US$1.28m). Minor Risk Share price has been volatile over the past 3 months (7.9% average weekly change).Valuation Update With 7 Day Price Move • Aug 28Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹78.99, the stock trades at a trailing P/E ratio of 11.1x. Average trailing P/E is 27x in the Diversified Financial industry in India. Total returns to shareholders of 220% over the past three years.Valuation Update With 7 Day Price Move • Jul 24Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹72.50, the stock trades at a trailing P/E ratio of 9.1x. Average trailing P/E is 31x in the Diversified Financial industry in India. Total returns to shareholders of 194% over the past three years.공고 • Jul 10+ 1 more updateChemo Pharma Laboratories Limited, Annual General Meeting, Sep 23, 2024Chemo Pharma Laboratories Limited, Annual General Meeting, Sep 23, 2024, at 16:00 Indian Standard Time. Location: 5-kumud apartment co.op.hsg.soc.ltd, karnik road, chikan ghar, kalyan - 421301, thane IndiaValuation Update With 7 Day Price Move • Jul 10Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹58.00, the stock trades at a trailing P/E ratio of 7.2x. Average trailing P/E is 31x in the Diversified Financial industry in India. Total returns to shareholders of 124% over the past three years.공고 • May 12Chemo Pharma Laboratories Limited to Report Q4, 2024 Final Results on May 27, 2024Chemo Pharma Laboratories Limited announced that they will report Q4, 2024 final results on May 27, 2024Valuation Update With 7 Day Price Move • Mar 27Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹63.28, the stock trades at a trailing P/E ratio of 7.1x. Average trailing P/E is 24x in the Diversified Financial industry in India. Total returns to shareholders of 255% over the past three years.공고 • Jan 10Chemo Pharma Laboratories Limited to Report Q3, 2024 Results on Jan 29, 2024Chemo Pharma Laboratories Limited announced that they will report Q3, 2024 results on Jan 29, 2024Valuation Update With 7 Day Price Move • Jan 10Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹75.63, the stock trades at a trailing P/E ratio of 13.7x. Average trailing P/E is 26x in the Diversified Financial industry in India. Total returns to shareholders of 119% over the past three years.Valuation Update With 7 Day Price Move • Dec 19Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₹57.37, the stock trades at a trailing P/E ratio of 10.4x. Average trailing P/E is 25x in the Diversified Financial industry in India. Total returns to shareholders of 190% over the past three years.Valuation Update With 7 Day Price Move • Oct 26Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹37.15, the stock trades at a trailing P/E ratio of 6x. Average trailing P/E is 27x in the Diversified Financial industry in India. Total returns to shareholders of 106% over the past three years.Board Change • Sep 02Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Non-Executive Independent Director Nand Pareek was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공고 • Aug 30+ 2 more updatesChemo Pharma Laboratories Limited to Report Fiscal Year 2024 Results on May 30, 2024Chemo Pharma Laboratories Limited announced that they will report fiscal year 2024 results on May 30, 2024New Risk • Aug 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m (₹11m revenue, or US$134k). Market cap is less than US$10m (₹57.5m market cap, or US$693.4k). Minor Risk Share price has been volatile over the past 3 months (7.3% average weekly change).Valuation Update With 7 Day Price Move • Aug 03Investor sentiment improves as stock rises 28%After last week's 28% share price gain to ₹34.81, the stock trades at a trailing P/E ratio of 5.6x. Average trailing P/E is 26x in the Diversified Financial industry in India. Total returns to shareholders of 404% over the past three years.공고 • Jul 15+ 1 more updateChemo Pharma Laboratories Limited to Report Q1, 2024 Results on Jul 27, 2023Chemo Pharma Laboratories Limited announced that they will report Q1, 2024 results at 3:30 PM, Indian Standard Time on Jul 27, 2023공고 • May 26Chemo Pharma Laboratories Limited Announces Executive ChangesChemo Pharma Laboratories Limited announced at the board meeting held on May 24, 2023 that the company approved Appointment of Unnati Jain, Company Secretary and Compliance Officers of the Company. Ms. Unnatti Jain aged 32 years is a qualified Company Secretary and a Bachelor of Commerce Graduate. She has worked with public and private limited companics as a Company Secretary. She has vast experience in the field of Companies Act, SEBI Rules and Regulation, LODR and related work. Her knowledge and experience in the legal and compliance field will help the company in a significant way. Mr. Ashok Somani as ceased to Compliance Officer of the Company.공고 • May 17Chemo Pharma Laboratories Limited to Report Q4, 2023 Results on May 24, 2023Chemo Pharma Laboratories Limited announced that they will report Q4, 2023 results at 3:30 PM, Indian Standard Time on May 24, 2023Valuation Update With 7 Day Price Move • Jan 19Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹40.00, the stock trades at a trailing P/E ratio of 13.3x. Average trailing P/E is 21x in the Diversified Financial industry in India. Total returns to shareholders of 433% over the past three years.공고 • Jan 05Chemo Pharma Laboratories Limited to Report Q3, 2023 Results on Jan 31, 2023Chemo Pharma Laboratories Limited announced that they will report Q3, 2023 results on Jan 31, 2023공고 • Dec 27Chemo Pharma Laboratories Limited Announces Management ChangesChemo Pharma Laboratories Limited informed that the Board of Directors of the Company at their meeting held on December 26, 2022, have discussed and approved the resignation of Ms. Neha Vora as a Company Secretary and Compliance Officer of the Company with effect from December 15, 2022 and approved the appointment of Mr. Ashok Somani, Director as Compliance Officer of the Company with effect from December 26, 2022.공고 • Dec 16Chemo Pharma Laboratories Limited Announces Resignation of Neha Vora as Company Secretary / Compliance OfficerChemo Pharma Laboratories Limited informed that Ms. Neha Vora, an Associate Member of the Institute of Company Secretaries of India having membership no.A30747, has resigned from the position of the Company Secretary & Compliance Officer of the Company with effect from end of the office hours on December 15, 2022.Valuation Update With 7 Day Price Move • Nov 30Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹41.55, the stock trades at a trailing P/E ratio of 13.8x. Average trailing P/E is 20x in the Diversified Financial industry in India. Total returns to shareholders of 560% over the past three years.공고 • Oct 14Chemo Pharma Laboratories Limited to Report Q2, 2023 Results on Oct 20, 2022Chemo Pharma Laboratories Limited announced that they will report Q2, 2023 results on Oct 20, 2022공고 • Jul 21+ 1 more updateChemo Pharma Laboratories Limited, Annual General Meeting, Sep 08, 2022Chemo Pharma Laboratories Limited, Annual General Meeting, Sep 08, 2022, at 16:00 Indian Standard Time. Location: 5-Kumud Apartment Co. op. Hsg. Soc. Ltd. Karnik Road, Chikan Ghar, Kalyan Thane IndiaValuation Update With 7 Day Price Move • Jun 29Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹38.95, the stock trades at a trailing P/E ratio of 10.4x. Average trailing P/E is 19x in the Diversified Financial industry in India. Total returns to shareholders of 399% over the past three years.Valuation Update With 7 Day Price Move • Jun 29Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹38.95, the stock trades at a trailing P/E ratio of 10.4x. Average trailing P/E is 19x in the Diversified Financial industry in India. Total returns to shareholders of 399% over the past three years.공고 • May 18Chemo Pharma Laboratories Limited to Report Q4, 2022 Results on May 27, 2022Chemo Pharma Laboratories Limited announced that they will report Q4, 2022 results on May 27, 2022Valuation Update With 7 Day Price Move • Jan 03Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₹34.40, the stock trades at a trailing P/E ratio of 24.7x. Average trailing P/E is 19x in the Diversified Financial industry in India. Total returns to shareholders of 21% over the past three years.Valuation Update With 7 Day Price Move • Apr 20Investor sentiment improved over the past weekAfter last week's 19% share price gain to ₹23.10, the stock trades at a trailing P/E ratio of 13.9x. Average trailing P/E is 13x in the Diversified Financial industry in India. Total loss to shareholders of 35% over the past three years.공고 • Jan 29+ 1 more updateChemo Pharma Laboratories Limited Appoints Bhavin Sheth as Chief Executive OfficerChemo Pharma Laboratories Limited at its board meeting held on January 28, 2021 approved the appointment of Shri. Bhavin Sheth as Chief Executive Officer of the company.공고 • Jan 12Chemo Pharma Laboratories Limited to Report Q3, 2021 Results on Jan 28, 2021Chemo Pharma Laboratories Limited announced that they will report Q3, 2021 results on Jan 28, 2021Is New 90 Day High Low • Dec 28New 90-day high: ₹22.80The company is up 17% from its price of ₹19.43 on 29 September 2020. The Indian market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Diversified Financial industry, which is up 26% over the same period.Valuation Update With 7 Day Price Move • Dec 24Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹21.75, the stock is trading at a trailing P/E ratio of 12x, up from the previous P/E ratio of 10.5x. This compares to an average P/E of 13x in the Diversified Financial industry in India. Total return to shareholders over the past three years is a loss of 49%.Valuation Update With 7 Day Price Move • Dec 10Market bids up stock over the past weekAfter last week's 17% share price gain to ₹16.95, the stock is trading at a trailing P/E ratio of 9.4x, up from the previous P/E ratio of 8x. This compares to an average P/E of 13x in the Diversified Financial industry in India. Total return to shareholders over the past three years is a loss of 62%.공고 • Nov 12+ 1 more updateChemo Pharma Laboratories Limited Announces Sad Demise of Shreeniwas Somani, Chairman and Whole Time DirectorChemo Pharma Laboratories Limited announced sad demise of Shri. Shreeniwas Somani, Chairman and Whole Time Director of the Company who passed away on November 10, 2020 at night.공고 • Oct 10Chemo Pharma Laboratories Limited to Report Q2, 2021 Results on Oct 19, 2020Chemo Pharma Laboratories Limited announced that they will report Q2, 2021 results on Oct 19, 2020Is New 90 Day High Low • Sep 24New 90-day high: ₹17.97The company is up 165% from its price of ₹6.78 on 16 June 2020. The Indian market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Diversified Financial industry, which is down 4.0% over the same period.공고 • Aug 11Chemo Pharma Laboratories Limited to Report Q1, 2021 Results on Aug 18, 2020Chemo Pharma Laboratories Limited announced that they will report Q1, 2021 results on Aug 18, 2020공고 • Jun 17Chemo Pharma Laboratories Limited to Report Q4, 2020 Results on Jun 26, 2020Chemo Pharma Laboratories Limited announced that they will report Q4, 2020 results on Jun 26, 2020지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 506365 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: 506365 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Starsource Multitrade 배당 수익률 vs 시장506365의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (506365)n/a시장 하위 25% (IN)0.3%시장 상위 25% (IN)1.4%업계 평균 (Pharmaceuticals)0.7%분석가 예측 (506365) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 506365 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 506365 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 506365 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: 506365 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YIN 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/08/16 10:44종가2026/08/14 00:00수익2026/06/30연간 수익2026/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Starsource Multitrade Limited는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • Aug 16First quarter 2027 earnings released: EPS: ₹0.14 (vs ₹78.70 loss in 1Q 2026)First quarter 2027 results: EPS: ₹0.14 (up from ₹78.70 loss in 1Q 2026). Revenue: ₹745.9k (up 260% from 1Q 2026). Net income: ₹209.8k (up ₹118.3m from 1Q 2026). Profit margin: 28% (up from net loss in 1Q 2026). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 133 percentage points per year, which is a significant difference in performance.
공고 • Aug 11Starsource Multitrade Limited to Report Q1, 2027 Results on Aug 14, 2026Starsource Multitrade Limited announced that they will report Q1, 2027 results on Aug 14, 2026
New Risk • Jul 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 77% per year over the past 5 years. Revenue is less than US$1m (₹5.5m revenue, or US$58k). Market cap is less than US$10m (₹139.0m market cap, or US$1.46m). Minor Risk Share price has been volatile over the past 3 months (7.7% average weekly change).
Reported Earnings • May 31Full year 2026 earnings released: ₹79.03 loss per share (vs ₹2.28 profit in FY 2025)Full year 2026 results: ₹79.03 loss per share (down from ₹2.28 profit in FY 2025). Revenue: ₹5.50m (down 11% from FY 2025). Net loss: ₹118.5m (down ₹122.0m from profit in FY 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 171 percentage points per year, which is a significant difference in performance.
공고 • May 25Starsource Multitrade Limited to Report Q4, 2026 Results on May 29, 2026Starsource Multitrade Limited announced that they will report Q4, 2026 results on May 29, 2026
Reported Earnings • Feb 14Third quarter 2026 earnings released: ₹0.58 loss per share (vs ₹1.17 loss in 3Q 2025)Third quarter 2026 results: ₹0.58 loss per share (improved from ₹1.17 loss in 3Q 2025). Net loss: ₹865.1k (loss narrowed 51% from 3Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 165 percentage points per year, which is a significant difference in performance.
공고 • Feb 09Starsource Multitrade Limited to Report Q3, 2026 Results on Feb 12, 2026Starsource Multitrade Limited announced that they will report Q3, 2026 results on Feb 12, 2026
공고 • Nov 10Starsource Multitrade Limited to Report Q2, 2026 Results on Nov 13, 2025Starsource Multitrade Limited announced that they will report Q2, 2026 results on Nov 13, 2025
New Risk • Oct 03New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 8.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.3% average weekly change). Earnings have declined by 47% per year over the past 5 years. Revenue is less than US$1m (₹3.4m revenue, or US$38k). Market cap is less than US$10m (₹198.0m market cap, or US$2.23m).
공고 • Sep 26+ 2 more updatesChemo Pharma Laboratories Limited Announces Changes to Its BoardChemo Pharma Laboratories Limited Limited announced in the 83rd annual general meeting held on September 24, 2025, the company approved the appointment and regularization of Ms. Sarvagya Goel as independent director of the company, appointment and regularization of Ms. Shiply Chopra as Independent Director of the company, appointment and regularization of Ms. Simran Utsav Trivedi as independent director of the company and appointment and regularization of Mr. Utsav trivedi as Executive director. Appointment and regularization of ruchit Mehta as Managing director.
New Risk • Sep 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 47% per year over the past 5 years. Revenue is less than US$1m (₹3.4m revenue, or US$38k). Market cap is less than US$10m (₹187.0m market cap, or US$2.12m). Minor Risk Share price has been volatile over the past 3 months (6.6% average weekly change).
New Risk • Aug 14New major risk - Revenue and earnings growthEarnings have declined by 47% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 47% per year over the past 5 years. Revenue is less than US$1m (₹3.4m revenue, or US$39k). Market cap is less than US$10m (₹202.4m market cap, or US$2.31m).
공고 • Aug 13Chemo Pharma Laboratories Limited, Annual General Meeting, Sep 24, 2025Chemo Pharma Laboratories Limited, Annual General Meeting, Sep 24, 2025, at 16:00 Indian Standard Time.
공고 • Aug 05Chemo Pharma Laboratories Limited to Report Q1, 2026 Results on Aug 12, 2025Chemo Pharma Laboratories Limited announced that they will report Q1, 2026 results on Aug 12, 2025
Valuation Update With 7 Day Price Move • May 26Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹146, the stock trades at a trailing P/E ratio of 56.1x. Average trailing P/E is 26x in the Diversified Financial industry in India. Total returns to shareholders of 306% over the past three years.
공고 • May 14Chemo Pharma Laboratories Limited to Report Q4, 2025 Results on May 29, 2025Chemo Pharma Laboratories Limited announced that they will report Q4, 2025 results on May 29, 2025
공고 • Apr 23Chemo Pharma Laboratories Limited Approves the Appointment of Bhawna Rajput as Company Secretary and Compliance Officer, Effective 16 April, 2025Chemo Pharma Laboratories Limited announced that at the board meeting held on April 16, 2025, approved the appointment of CS Bhawna Rajput as Company Secretary and Compliance Officer of the Company with effect from 16 April, 2025.
공고 • Apr 08+ 2 more updatesChemo Pharma Laboratories Limited Announces Board and Executive ResignationsChemo Pharma Laboratories Limited announced the resignation of Mr. Bhavin Sheth from the position of Executive Director of the Company; resignation of Shri. Ashok Somani from the position of Executive Director of the Company; resignation of Mrs. Shanta Somani from the position of Non-Executive Director of the Company; resignation of Shri. Mathura Prasad Sharma, from the position of Directorship of the Company in the category of Non-Executive Independent Director; resignation of Shri Toby Antony from the position of Directorship of the Company in the category of Non- Executive Independent Director; resignation of Shri Nandkumar Pareek from the position of Directorship of the Company in the category of Non-Executive Independent Director; resignation of Mrs. Unnatti Jain, from the position of Company Secretary and Compliance Officer of the Company.
Valuation Update With 7 Day Price Move • Feb 12Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹63.05, the stock trades at a trailing P/E ratio of 24.2x. Average trailing P/E is 25x in the Diversified Financial industry in India. Total returns to shareholders of 45% over the past three years.
New Risk • Jan 28New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 38% Last year net profit margin: 90% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Revenue is less than US$1m (₹10m revenue, or US$119k). Market cap is less than US$10m (₹127.7m market cap, or US$1.48m). Minor Risk Profit margins are more than 30% lower than last year (38% net profit margin).
공고 • Jan 13Chemo Pharma Laboratories Limited to Report Q3, 2025 Results on Jan 27, 2025Chemo Pharma Laboratories Limited announced that they will report Q3, 2025 results on Jan 27, 2025
Valuation Update With 7 Day Price Move • Dec 19Investor sentiment deteriorates as stock falls 22%After last week's 22% share price decline to ₹98.45, the stock trades at a trailing P/E ratio of 11.9x. Average trailing P/E is 29x in the Diversified Financial industry in India. Total returns to shareholders of 234% over the past three years.
Valuation Update With 7 Day Price Move • Dec 04Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹93.82, the stock trades at a trailing P/E ratio of 11.3x. Average trailing P/E is 27x in the Diversified Financial industry in India. Total returns to shareholders of 206% over the past three years.
Valuation Update With 7 Day Price Move • Nov 04Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹82.72, the stock trades at a trailing P/E ratio of 10x. Average trailing P/E is 29x in the Diversified Financial industry in India. Total returns to shareholders of 172% over the past three years.
공고 • Oct 15Chemo Pharma Laboratories Limited to Report Q2, 2025 Results on Oct 28, 2024Chemo Pharma Laboratories Limited announced that they will report Q2, 2025 results on Oct 28, 2024
Valuation Update With 7 Day Price Move • Oct 10Investor sentiment improves as stock rises 31%After last week's 31% share price gain to ₹86.07, the stock trades at a trailing P/E ratio of 12.1x. Average trailing P/E is 28x in the Diversified Financial industry in India. Total returns to shareholders of 246% over the past three years.
New Risk • Aug 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m (₹17m revenue, or US$204k). Market cap is less than US$10m (₹107.8m market cap, or US$1.28m). Minor Risk Share price has been volatile over the past 3 months (7.9% average weekly change).
Valuation Update With 7 Day Price Move • Aug 28Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹78.99, the stock trades at a trailing P/E ratio of 11.1x. Average trailing P/E is 27x in the Diversified Financial industry in India. Total returns to shareholders of 220% over the past three years.
Valuation Update With 7 Day Price Move • Jul 24Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹72.50, the stock trades at a trailing P/E ratio of 9.1x. Average trailing P/E is 31x in the Diversified Financial industry in India. Total returns to shareholders of 194% over the past three years.
공고 • Jul 10+ 1 more updateChemo Pharma Laboratories Limited, Annual General Meeting, Sep 23, 2024Chemo Pharma Laboratories Limited, Annual General Meeting, Sep 23, 2024, at 16:00 Indian Standard Time. Location: 5-kumud apartment co.op.hsg.soc.ltd, karnik road, chikan ghar, kalyan - 421301, thane India
Valuation Update With 7 Day Price Move • Jul 10Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹58.00, the stock trades at a trailing P/E ratio of 7.2x. Average trailing P/E is 31x in the Diversified Financial industry in India. Total returns to shareholders of 124% over the past three years.
공고 • May 12Chemo Pharma Laboratories Limited to Report Q4, 2024 Final Results on May 27, 2024Chemo Pharma Laboratories Limited announced that they will report Q4, 2024 final results on May 27, 2024
Valuation Update With 7 Day Price Move • Mar 27Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹63.28, the stock trades at a trailing P/E ratio of 7.1x. Average trailing P/E is 24x in the Diversified Financial industry in India. Total returns to shareholders of 255% over the past three years.
공고 • Jan 10Chemo Pharma Laboratories Limited to Report Q3, 2024 Results on Jan 29, 2024Chemo Pharma Laboratories Limited announced that they will report Q3, 2024 results on Jan 29, 2024
Valuation Update With 7 Day Price Move • Jan 10Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹75.63, the stock trades at a trailing P/E ratio of 13.7x. Average trailing P/E is 26x in the Diversified Financial industry in India. Total returns to shareholders of 119% over the past three years.
Valuation Update With 7 Day Price Move • Dec 19Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₹57.37, the stock trades at a trailing P/E ratio of 10.4x. Average trailing P/E is 25x in the Diversified Financial industry in India. Total returns to shareholders of 190% over the past three years.
Valuation Update With 7 Day Price Move • Oct 26Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹37.15, the stock trades at a trailing P/E ratio of 6x. Average trailing P/E is 27x in the Diversified Financial industry in India. Total returns to shareholders of 106% over the past three years.
Board Change • Sep 02Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Non-Executive Independent Director Nand Pareek was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공고 • Aug 30+ 2 more updatesChemo Pharma Laboratories Limited to Report Fiscal Year 2024 Results on May 30, 2024Chemo Pharma Laboratories Limited announced that they will report fiscal year 2024 results on May 30, 2024
New Risk • Aug 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m (₹11m revenue, or US$134k). Market cap is less than US$10m (₹57.5m market cap, or US$693.4k). Minor Risk Share price has been volatile over the past 3 months (7.3% average weekly change).
Valuation Update With 7 Day Price Move • Aug 03Investor sentiment improves as stock rises 28%After last week's 28% share price gain to ₹34.81, the stock trades at a trailing P/E ratio of 5.6x. Average trailing P/E is 26x in the Diversified Financial industry in India. Total returns to shareholders of 404% over the past three years.
공고 • Jul 15+ 1 more updateChemo Pharma Laboratories Limited to Report Q1, 2024 Results on Jul 27, 2023Chemo Pharma Laboratories Limited announced that they will report Q1, 2024 results at 3:30 PM, Indian Standard Time on Jul 27, 2023
공고 • May 26Chemo Pharma Laboratories Limited Announces Executive ChangesChemo Pharma Laboratories Limited announced at the board meeting held on May 24, 2023 that the company approved Appointment of Unnati Jain, Company Secretary and Compliance Officers of the Company. Ms. Unnatti Jain aged 32 years is a qualified Company Secretary and a Bachelor of Commerce Graduate. She has worked with public and private limited companics as a Company Secretary. She has vast experience in the field of Companies Act, SEBI Rules and Regulation, LODR and related work. Her knowledge and experience in the legal and compliance field will help the company in a significant way. Mr. Ashok Somani as ceased to Compliance Officer of the Company.
공고 • May 17Chemo Pharma Laboratories Limited to Report Q4, 2023 Results on May 24, 2023Chemo Pharma Laboratories Limited announced that they will report Q4, 2023 results at 3:30 PM, Indian Standard Time on May 24, 2023
Valuation Update With 7 Day Price Move • Jan 19Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹40.00, the stock trades at a trailing P/E ratio of 13.3x. Average trailing P/E is 21x in the Diversified Financial industry in India. Total returns to shareholders of 433% over the past three years.
공고 • Jan 05Chemo Pharma Laboratories Limited to Report Q3, 2023 Results on Jan 31, 2023Chemo Pharma Laboratories Limited announced that they will report Q3, 2023 results on Jan 31, 2023
공고 • Dec 27Chemo Pharma Laboratories Limited Announces Management ChangesChemo Pharma Laboratories Limited informed that the Board of Directors of the Company at their meeting held on December 26, 2022, have discussed and approved the resignation of Ms. Neha Vora as a Company Secretary and Compliance Officer of the Company with effect from December 15, 2022 and approved the appointment of Mr. Ashok Somani, Director as Compliance Officer of the Company with effect from December 26, 2022.
공고 • Dec 16Chemo Pharma Laboratories Limited Announces Resignation of Neha Vora as Company Secretary / Compliance OfficerChemo Pharma Laboratories Limited informed that Ms. Neha Vora, an Associate Member of the Institute of Company Secretaries of India having membership no.A30747, has resigned from the position of the Company Secretary & Compliance Officer of the Company with effect from end of the office hours on December 15, 2022.
Valuation Update With 7 Day Price Move • Nov 30Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹41.55, the stock trades at a trailing P/E ratio of 13.8x. Average trailing P/E is 20x in the Diversified Financial industry in India. Total returns to shareholders of 560% over the past three years.
공고 • Oct 14Chemo Pharma Laboratories Limited to Report Q2, 2023 Results on Oct 20, 2022Chemo Pharma Laboratories Limited announced that they will report Q2, 2023 results on Oct 20, 2022
공고 • Jul 21+ 1 more updateChemo Pharma Laboratories Limited, Annual General Meeting, Sep 08, 2022Chemo Pharma Laboratories Limited, Annual General Meeting, Sep 08, 2022, at 16:00 Indian Standard Time. Location: 5-Kumud Apartment Co. op. Hsg. Soc. Ltd. Karnik Road, Chikan Ghar, Kalyan Thane India
Valuation Update With 7 Day Price Move • Jun 29Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹38.95, the stock trades at a trailing P/E ratio of 10.4x. Average trailing P/E is 19x in the Diversified Financial industry in India. Total returns to shareholders of 399% over the past three years.
Valuation Update With 7 Day Price Move • Jun 29Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹38.95, the stock trades at a trailing P/E ratio of 10.4x. Average trailing P/E is 19x in the Diversified Financial industry in India. Total returns to shareholders of 399% over the past three years.
공고 • May 18Chemo Pharma Laboratories Limited to Report Q4, 2022 Results on May 27, 2022Chemo Pharma Laboratories Limited announced that they will report Q4, 2022 results on May 27, 2022
Valuation Update With 7 Day Price Move • Jan 03Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₹34.40, the stock trades at a trailing P/E ratio of 24.7x. Average trailing P/E is 19x in the Diversified Financial industry in India. Total returns to shareholders of 21% over the past three years.
Valuation Update With 7 Day Price Move • Apr 20Investor sentiment improved over the past weekAfter last week's 19% share price gain to ₹23.10, the stock trades at a trailing P/E ratio of 13.9x. Average trailing P/E is 13x in the Diversified Financial industry in India. Total loss to shareholders of 35% over the past three years.
공고 • Jan 29+ 1 more updateChemo Pharma Laboratories Limited Appoints Bhavin Sheth as Chief Executive OfficerChemo Pharma Laboratories Limited at its board meeting held on January 28, 2021 approved the appointment of Shri. Bhavin Sheth as Chief Executive Officer of the company.
공고 • Jan 12Chemo Pharma Laboratories Limited to Report Q3, 2021 Results on Jan 28, 2021Chemo Pharma Laboratories Limited announced that they will report Q3, 2021 results on Jan 28, 2021
Is New 90 Day High Low • Dec 28New 90-day high: ₹22.80The company is up 17% from its price of ₹19.43 on 29 September 2020. The Indian market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Diversified Financial industry, which is up 26% over the same period.
Valuation Update With 7 Day Price Move • Dec 24Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹21.75, the stock is trading at a trailing P/E ratio of 12x, up from the previous P/E ratio of 10.5x. This compares to an average P/E of 13x in the Diversified Financial industry in India. Total return to shareholders over the past three years is a loss of 49%.
Valuation Update With 7 Day Price Move • Dec 10Market bids up stock over the past weekAfter last week's 17% share price gain to ₹16.95, the stock is trading at a trailing P/E ratio of 9.4x, up from the previous P/E ratio of 8x. This compares to an average P/E of 13x in the Diversified Financial industry in India. Total return to shareholders over the past three years is a loss of 62%.
공고 • Nov 12+ 1 more updateChemo Pharma Laboratories Limited Announces Sad Demise of Shreeniwas Somani, Chairman and Whole Time DirectorChemo Pharma Laboratories Limited announced sad demise of Shri. Shreeniwas Somani, Chairman and Whole Time Director of the Company who passed away on November 10, 2020 at night.
공고 • Oct 10Chemo Pharma Laboratories Limited to Report Q2, 2021 Results on Oct 19, 2020Chemo Pharma Laboratories Limited announced that they will report Q2, 2021 results on Oct 19, 2020
Is New 90 Day High Low • Sep 24New 90-day high: ₹17.97The company is up 165% from its price of ₹6.78 on 16 June 2020. The Indian market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Diversified Financial industry, which is down 4.0% over the same period.
공고 • Aug 11Chemo Pharma Laboratories Limited to Report Q1, 2021 Results on Aug 18, 2020Chemo Pharma Laboratories Limited announced that they will report Q1, 2021 results on Aug 18, 2020
공고 • Jun 17Chemo Pharma Laboratories Limited to Report Q4, 2020 Results on Jun 26, 2020Chemo Pharma Laboratories Limited announced that they will report Q4, 2020 results on Jun 26, 2020